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Abstract
Drug resistance is often a limiting factor in successful chemotherapy. Our laboratory has been interested in studying mechanisms of
resistance to drugs that are targeted to the thymidylate biosynthesis pathway especially those that target thymidylate synthase (TS) and
dihydrofolate reductase (DHFR). We have used leukemia as a model system to study resistance to methotrexate (MTX) and colorectal cancer
as the model system to study 5-fluorouracil (5-FU) resistance. In leukemias, we and others have shown that transport, efflux,
polyglutamylation and hydrolase activities are major determinants of MTX resistance. We have further reported that some leukemic cells
have an increase in DHFR gene copy number possibly contributing to the resistant phenotype. Recently, we have begun to study in detail the
molecular mechanisms that govern translational regulation of DHFR in response to MTX as an additional resistance mechanism. Studies thus
far involving colorectal tumors obtained from patients have focused predominantly on the predictive value of levels of TS expression and p53
mutations in determining response to 5-FU. Although the predictive value of these two measures appears to be significant, given the variety
of resistance to 5-FU observed in cell lines, it is not likely that these are the only measures predictive of response or responsible for acquired
resistance to this drug. The enzyme uridine–cytidine monophosphate kinase (UMPK) is an essential and rate-limiting enzyme in 5-FU
activation while dihydropyrimidine dehydrogenase (DPD) is a catabolic enzyme that inactivates 5-FU. Alterations in UMPK and DPD may
therefore explain failure of 5-FU response in the absence of alterations in TS or p53. Transcription factors that regulate TS may also influence
drug sensitivity. We have found that mRNA levels of the E2F family of transcription factors correlates with TS message levels and are higher
in lung metastases than in liver metastases of colorectal cancers. Moreover, gene copy number of the E2F-1 gene appears to be increased in a
significant number of samples obtained from metastases of colorectal cancer. We have also generated mutants of both DHFR and TS that
confer resistance to MTX as well as 5-FU by random as well as site-directed mutagenesis. These mutants used alone or as fusion cDNAs of
the mutants have proven to be useful in transplant studies where transfer of these mutant cDNAs to bone marrow cells have been shown to
confer drug resistance to recipients. The fusion cDNAs of DHFR such as the DHFR–herpes simplex virus type 1 thymidine kinase (HSVTK)
are also useful for regulation of gene expression in vivo using MTX as the small molecule regulator that can be monitored by positron
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1. Introduction
A major problem in chemotherapy is resistance to the
chemotherapeutic agents. There are generally two major
forms of resistance encountered in the clinic. One is intrinsic
resistance, which is an innate property of the tumor cells and
is not triggered by drug exposure. The other is known as
acquired resistance, which occurs following exposure to the
drug(s). Antifolates such as methotrexate (MTX) and fluo-
ropyrimidines such as 5-fluorouracil (5-FU) have been used
in the clinic for the management of childhood acute lym-
phoblastic leukemias (ALL) and colorectal cancer, respec-
tively, with modest success. Laboratory studies carried out
over the years, on cell culture models as well tumor samples
from blood and biopsy materials, have revealed a wealth of
information regarding mechanisms of resistance to both
these drugs.
MTX, in combination with other chemotherapeutic
agents, has been used for treatment of malignancies includ-
ing ALL, non-Hodgkin’s lymphoma, osteogenic sarcoma,
choriocarcinoma and carcinomas of breast, head and neck.
In addition to the use of MTX for treatment of malignancies,
it is also used for treatment of nonmalignant conditions such
as rheumatoid arthritis, psoriasis and in the prevention of
graft versus host disease [1]. Although response to treatment
is observed in patients, many of them relapse due to
development of resistance. The underlying mechanisms
responsible for resistance to MTX have been the subject
of intense investigation for the past decade.
The primary cellular target of MTX, and other antifolates,
is the enzyme dihydrofolate reductase (DHFR), which cata-
lyzes the reduction of folate and 7,8 dihydrofolate to 5,6,7,8
tetrahydrofolate [2]. To act on this intracellular target, MTX
enters the cell primarily by an active carrier transport
mechanism also shared by the reduced folates and mediated
by the reduced folate carrier (RFC) [3]. Once inside the cell,
MTX is modified so that it is retained in the cell. This is
accomplished by addition of glutamate residues (up to five)
catalyzed by the enzyme folylpolyglutamate synthetase
(FPGS) [4,5]. MTX and polyglutamylated forms of MTX
are tight binding inhibitors of DHFR and interfere with
pyrimidine viz. thymidylate biosynthesis. MTX polygluta-
mates as well as dihydrofolate polyglutamates are also
inhibitors of enzymes involved in purine biosynthesis includ-
ing 5V-phosphoribosylglycinamide transformylase (GAR
transformylase) and aminoimidazole carboxamide ribonu-
cleotide transformylase (AICAR transformylase) [6–8].
Enzymatic removal of glutamyl groups from polyglutamy-
lated forms of both folates and MTX is catalyzed by gamma
glutamyl hydrolase (GGH). This enzymemaintains a balance
between the various glutamylated forms in concert with
FPGS [9–12].
2. Mechanisms of resistance
In experimental cell culture model systems, four common
mechanisms of resistance to MTX have been identified;
decreased uptake of the drug, decreased retention due to
defective polyglutamylation or increased polyglutamate
breakdown, increased DHFR activity as well as decreased
binding of MTX to DHFR [13].
2.1. Transport
The most common mechanism of resistance to MTX is
defective transport of the drug. This is true for cell culture
model systems as well as leukemic blast cells from patients
with ALL and osteogenic sarcoma at the time of relapse
after MTX treatment. This is an example of acquired
resistance to MTX after acute or chronic exposure to
MTX [14–16]. With the recent cloning of the gene encod-
ing the mouse as well as the human RFC, it is now possible
to determine the molecular basis of resistance in cells that
have impaired MTX uptake [16–19]. Using a complemen-
tation assay, a mouse cDNA clone has been identified that
partially restores the transport defect in a human breast
cancer cell line ZR75 [18]. This gene codes for a protein of
58 kDa and has structural similarity with the human glucose
transporter GLUT1. Hydropathy analysis has revealed that it
contains 12 transmembrane domains and belongs to the
superfamily of transporter molecules collectively referred to
as the major facilitator superfamily, members of which carry
out sugar transport in mammalian cells [20]. The human
cDNA clone that complement transport defect in a Chinese
hamster ovary cell line encodes a putative RFC of 64 kDa
with approximately 50% homology to the hamster and
mouse RFCs at the amino acid level [19]. Yang et al. [21]
have identified mutations in the human RFC protein as
major determinants of MTX resistance in leukemia and
osteogenic sarcoma patient samples.
2.2. Polyglutamylation
MTX, upon entry into the cell, is modified by the
sequential addition of glutamate residues catalyzed by the
enzyme FPGS. The ability to form long chain polygluta-
mates of MTX correlates well with the therapeutic outcome
of several leukemias. Adult T and B lineage ALL have been
found to accumulate lower amounts of long chain poly-
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glutamates as compared to pediatric B lineage ALL and this
correlates with poorer prognosis for the former [22–25].
Pediatric T lineage ALL was also seen to accumulate less
long chain polyglutamates as compared to its B lineage
counterpart [25]. Nonhyperdiploid B lineage blasts were
also found to accumulate significantly less long chain
polyglutamates once again correlating with outcome [24].
The ability to polyglutamylate has now been accepted to be
an important determinant of outcome of leukemias, most
likely through predicting response to MTX. It is of interest
to note that the monoblastic subset of acute myeloid
leukemia (AML) Franco American British (FAB) classifi-
cation-M5 subtype was found to form polyglutamates of
MTX as efficiently as childhood ALL blasts [26]. MTX may
be an effective therapy for this subtype and may have been
overlooked because other subtypes of AML are intrinsically
resistant to MTX. Lack of accumulation of MTX polyglu-
tamates may be due lack of formation of long chain
polyglutamates due to impaired activity of FPGS or due to
enhanced breakdown of the formed long chain polygluta-
mates due to increased activity of GGH [27]. The relative
contribution of FPGS and GGH to overall MTX resistance
remains an area of active investigation. Mammalian FPGS
has molecular mass of 60 kDa and catalyzes the addition of
glutamates to all naturally occurring folates as well some
folate analogs such as MTX. Characterization of alterations
in FPGS at the molecular level will now be possible with the
recent cloning of the cDNA for human FPGS [28]. Using
sequence information made available recently a quantitative
polymerase chain reaction (PCR) method has been devel-
oped to measure FPGS mRNA levels in leukemic blasts.
FPGS mRNA expression using this method correlated well
with the enzyme activity levels [29]. Less is known about
the enzyme GGH as compared to FPGS. The hydrolases can
be classified broadly into two types; the lysosomal type with
a pH optimum around 4.4 and a cytoplasmic type with an
alkaline pH optimum with a restricted expression (small
intestine, brain). It appears that the lysosomal hydrolase is
more important in regulation of polyglutamate chain length.
The bovine hepatic enzyme remains the most well-charac-
terized lysosomal hydrolase to date. This enzyme has a
molecular mass of 108 kDa and contains highly reactive
sulfhydryl groups. Several laboratories including our own
are engaged in the purification and further molecular char-
acterization of GGH from tumor cells in an attempt to
understand the role of GGH in intrinsic and acquired
resistance to MTX [30,31]. Recently, Cole et al. [32] have
reported that transfection and overexpression of GGH in
HT-1080 human fibrosarcoma cells and MCF-7 human
breast carcinoma cells, unexpectedly, did not result in
MTX resistance. The clones overexpressing GGH were
not resistant to short-term MTX exposure although these
cells showed altered MTX accumulation and metabolism to
long-chain polyglutamates. Moreover, changes in MTX
metabolism were found to be balanced by alterations in
accumulation and metabolism of folic acid, suggesting that
ratio of MTX/folate accumulation may be a better predictor
of MTX effect than accumulation of either alone.
2.3. DHFR gene amplification
As MTX is a tight-binding inhibitor of the enzyme
DHFR, an increase in the level of intracellular DHFR would
be expected to cause MTX resistance. Exposure of tumor
cells to increasing doses of MTX results in amplification of
the DHFR gene. Initially, four case reports were published,
indicating that low-level gene amplification occurs in tumor
cells from patients treated with MTX [33a–36]. In a recent
study reported from this laboratory, approximately 30% of
relapsed ALL patients (9 of 29) had low level DHFR gene
amplification (two to four copies of the gene) as compared
to only 10% (4 of 38) of newly diagnosed ALL patients.
This study confirmed that low level DHFR gene amplifica-
tion is a mechanism of acquired resistance to MTX [36]. Of
interest, mutations in p53 gene were seen in 7 of 9 ALL
blast samples with DHFR amplification. In contrast, only 2
of 26 ALL blast samples without DHFR gene amplification
had p53 mutations [36]. In cell lines with mutated p53, a
tumor suppressor gene, amplification of the target gene has
been observed after antimetabolite exposure [37,38].
2.4. Mutations in DHFR
Mutant forms of DHFR with reduced affinity for MTX
have been identified in cell lines that were exposed to
increasing doses of the drug [39–44]. In order to examine
whether mutations in DHFR occur in patient samples, we
have tested blast samples from over 20 patients for decreased
binding of MTX to DHFR; in addition, we have analyzed the
complete DHFR cDNA sequence of eight patients; six ALL
(four relapsed and two untreated) and two patients with
untreated AML. No evidence for decreased binding at the
enzymatic level or alterations in the coding region of the
DHFR cDNA were found from these patient samples. It
seems unlikely that mutations in DHFR are a major mech-
anism of acquired resistance in patients exposed to MTX
[45a]. In contrast, mutations leading to a decreased affinity
of DHFR for the antifolate pyrimethamine, used in the
treatment of malaria, is the major cause of resistance to this
drug [45b].
2.5. Translational autoregulation of DHFR
Previous studies have shown that administration of MTX
to patients leads to an increase in the level of DHFR protein
in both normal and leukemic leukocytes as well as in
erythrocytes within hours to days [46]. Studies carried out
in vitro using a lymphoblastoid cell line showed that an
increase in DHFR protein is not transcriptionally mediated
but was abrogated by cycloheximide treatment, suggesting
that new protein synthesis was involved. The rapid increase
in DHFR observed after MTX treatment could have been
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due to either protection of DHFR from degradation by
bound MTX and/or dihydrofolate, or to an in increase in
translation of this enzyme [47]. An increase in thymidylate
synthase (TS) activity has been reported after 5-FU treat-
ment, and it has been suggested that this increase may be
due to regulation at the translational level [48]. Using a
rabbit reticulocyte translation system, we have found that
DHFR protein inhibited its own synthesis. The reversal of
this inhibition by MTX or FH2 may explain in part the
observed induction of DHFR activity in normal and leuke-
mic cells after MTX treatment [49a]. In order to locate the
region of DHFR mRNA involved in binding to the DHFR
protein, we used a system where 32P-labelled in vitro tran-
scribed RNA from different regions of the coding sequence
of DHFR mRNA is UV cross-linked to DHFR protein and
electrophoresed after RNAse treatment. Competition experi-
ments with molar excess of cold RNA fragments revealed
that a 100-base-long fragment in the coding region may be
involved in the binding [49b].
2.6. Cell cycle genes and resistance to antifolates
Loss of the functional retinoblastoma protein (pRb) may
also contribute to antimetabolite resistance as cells lacking
pRb may have increased levels of enzymes associated with
proliferation (e.g. DHFR, TS) as a consequence of increased
levels of free E2F, a transcription factor(s) that is normally
quenched by hypophosporylated pRb. When cells begin to
move out of G1 and into S phase, pRb becomes hyper-
phosphorylated and releases bound E2F, which then enhan-
ces the transcription of genes involved in DNA synthesis
[50]. We have observed that a human osteosarcoma cell line
SaOs2 that lacks pRb is intrinsically resistant to MTX and
fluoropyrimidines (FUDR) as compared to lines with pRb
present. This cell line has a higher level of DHFR and TS
and the increase in this activity is attributable to increased
trancriptional activity of DHFR and TS genes. When the
cDNA encoding pRb is reintroduced into this cell line,
sensitivity to MTX is restored. There are other human
sarcoma cell lines established in the laboratory that lack
pRb and these cell lines also show a similar resistance to
MTX and FUDR [51].
Since free or unbound E2F levels increase when pRb is
hyperphosphorylated, we reasoned that activation of regu-
lators of pRb phosphorylation like the cyclin dependent
kinase system (the cyclin D1–Cdk4) may also result in an
increase in DHFR levels and hence MTX resistance. Trans-
fection of cyclin D1 into HT-1080 human sarcoma cell line
resulted in an increase in MTX resistance in clones that
expressed high levels but not in clones that expressed low
levels of the gene, suggesting a direct relationship between
the level of cyclin D1 expression and DHFR transcription
[52]. Since certain tumors have been shown to express high
levels of cyclin D1, it will be interesting to examine the
relationship between overexpression of cyclin D1, DHFR
transcription and MTX sensitivity in these tumors. It is
becoming increasingly clear that deregulation of cell cycle
genes has a profound effect on antimetabolite resistance.
3. Resistance to fluorpyrimidines
3.1. Increased levels of TS
The levels of TS, the target enzyme of the fluoropyrimi-
dines, and antifolate inhibitors of TS, frequently correlates
with and may predict response to inhibitors of this enzyme.
Although fluoropyrimidines such as 5-FU have been used in
the clinic for colorectal cancer, drug resistance is still a
major hurdle to successful therapy. Studies have therefore
been undertaken to determine both intrinsic and acquired
resistance to 5-FU. Intrinsic resistance has mostly been
attributed to high levels of TS in tumors that occur as a
result of increased copy number or increased transcription/
translation of the message and protein. Determination of
factors that result in intrinsic resistance to fluoropyrimidines
may allow the clinician to separate the predicted nonres-
ponders from the group and provide them with more mean-
ingful chemotherapeutic options.
High TS levels generally predict for lack of response
while lower levels are correlated with response in colorectal
cancers [53–55]. Several groups have reported that TS
levels generally predict not only for response but also for
overall survival in colorectal cancers. Generally, mRNA
levels of TS have proven to be as good predictors of
response as well as protein levels determined by immuno-
histochemistry [53–57]. We have shown that lung meta-
stases, which are less responsive to fluoropyrimidine based
therapies, have a higher mean TS gene expression level than
hepatic metastases [58a,b]. It has been reported that abdomi-
nal metastasis had a higher level of TS gene expression than
hepatic metastasis, and this correlated well with response;
the hepatic metastasis being more responsive than the
abdominal metastasis group [59], suggesting that TS levels
vary among metastatic sites.
In a few cases, the increase in TS was attributable to
increased copy number while in others, the increase has been
suggested to be a result of increased E2F-1 levels [58a,b].
Increased levels of TS as a result of translational upregula-
tion or increased stability in the presence of fluoropyrimi-
dines has been shown to occur in cell culture model systems
[60,61]. The resultant increase in TS levels may also con-
tribute to the resistant phenotype, although the importance of
these mechanisms in human cancers is yet to be established.
Polymorphisms in theTSpromoter have also been reported
to be correlated with response. Patients who are homozygous
for a triple tandem repeat of a 28-bp sequence within the TS
promoter had a higher level of TS gene expression than
patients who were homozygous for a double tandem repeat
of the same 28-bp sequence while an intermediate response
pattern was observed for heterozygous patients [62]. Cell
culture models have identified several mutations in TS being
D. Banerjee et al. / Biochimica et Biophysica Acta 1587 (2002) 164–173 167
responsible for drug resistance; however, no examples of
mutant forms of TS have been reported in tumor samples
from patients resistant to fluoropyrimidines [63–65].
3.2. E2F levels
TS and other proteins involved in DNA synthesis such as
DHFR, thymidine kinase (TK), ribonucleotide reductase
(RR), and DNA Pol a are transcribed in the late G1 and
S-phase of the cell cycle. Regulation of cell cycle progres-
sion at the Gl checkpoint appears to be largely dependent
upon the ability of pRb and related proteins to sequester and
inhibit the activity of the E2F family of transcription factors,
which results in transcription of these enzymes. Disruption
of the pRb–E2F complex by phosphorylation of pRb by
Cdks or p16 dysfunction leads to ‘‘free’’ E2F, which can
then transactivate target genes such as TS. Studies on forced
overexpression of E2F-1 in cell culture by us and others
have indicated that increased expression of E2F-1 in these
cells is associated with an increase in TS levels and to a
lesser extent DHFR and TK levels [66–69]. In order to
understand the biochemical basis for the differential
response of hepatic metastases and pulmonary metastases
to fluoropyrimidine-based therapies, we have measured TS
mRNA and protein levels as well as levels of E2F-1 in
colorectal tumor samples. High TS mRNA levels were
found in lung metastasis as compared to liver metastasis
and correspondingly the E2F-1 levels were also higher in
lung metastasis compared to liver metastasis [58a,b]. Kasa-
hara et al. [70] have also reported a close correlation
between TS and E2F-1 levels in colon cancer.
Although E2F-1 overexpression is associated with cell
proliferation, high levels of E2F-1 have also been shown to
be apoptotic in many cell systems. Recent evidence suggests
that tumor cells, which express high levels of E2F-1, are
protected from apoptosis by deletion or mutation in genes
that could result in apoptotic cell death, including p53,
p14ARF and bax. Alterations in p53, p14ARF or mdm2
interfere with the cell’s ability to conduct the proapoptotic
signal allowing the high levels of E2F-1 to stimulate cell
proliferation [66,67]. Mutations in p53, p16, bax and
p14ARF occur frequently in colon cancer, and coupled with
high levels of E2F-1 point to a more aggressive phenotype
of the tumor. Along with the loss in the apoptotic signaling
pathway, overexpression of E2F-1 may also activate genes
whose products confer a more invasive phenotype. Interest-
ingly, recent reports indicate that forced over expression of
E2F-1 results in activation of the invasive phenotype [71].
Several studies using comparative genomic hybridization
(CGH), have shown that 20q is a region of frequent gain in
colorectal cancers and more specifically regions from
20q11.2 to 20q13 showed frequent gains. The chromosomal
location of E2F-1 is 20q11.2 and, therefore, based on
preliminary measurements of E2F-1 gene copy number in
metastatic tumors, we have reason to believe that gains in
this chromosomal region leads to an increase in copy num-
ber of E2F-1 in these tumors. We have analyzed the
available tumors for E2F-1 gene copy number by quantita-
tive DNA PCR and further confirmed that the copy number
of E2F-1 gene is increased in colorectal cancers (Iwamoto et
al., in preparation). Correlation of either TS levels or
response with other E2Fs is not clear at present.
3.3. Decreased UMPK as a mechanism of resistance to
5-FU
We had previously shown that decreased expression of
UMPK was a mechanism of resistance to pulse (4 h) Fura
exposure in a 5-FU resistant HCT8 cell line [72]. Using the
human UMPK as a positive control, we have performed real-
time fluorescent quantitative RT-PCR on 31 patient-derived
colon adenocarcinoma tumor samples. Of the 31, 8 patients
had not received any prior chemotherapy and had detectable
UMPK levels. In contrast, 10 of 23 previously treated patients
had no detectable expression of UMPK. This strongly sug-
gests that decreased UMPK expression is a mechanism of 5-
FU resistance (Banerjee et al., in preparation).
This is the first evidence for a correlation between lack of
UMPK expression and acquired resistance to 5-FU in
patients with colorectal cancer. As cytogenetic abnormalities
are common in the chromosomal region believed to contain
UMPK, we have begun to determine if this marked decrease
in UMPK expression is secondary to a genetic deletion or
mutation.
Decreased levels of the Fura-activating enzyme orotic
acid phosphoribosyl transferase (OPRTase) have also been
reported to be a cause of resistance to Fura in experimental
systems [73] although decreased activity of this enzyme has
not been found in tumors from patients resistant to 5-FU.
3.4. Thymidine phosphorylase (TP)
TP, also known as platelet-derived endothelial growth
factor, is an enzyme that catalyzes the phosphorolysis of
thymidine to 2-deoxy-D-ribose and thymine intracellularly.
Capecitabine, a new orally available fluoropyrimidine car-
bamate, is converted to 5-FU by the action of enzymes
including TP in the final step in tumors. Lack of TP would
then be associated with less intratumoral 5-FU generation
and therefore would be predicted to be less effective. The
angiogenic property of TP due to its endothelial growth
factor activity has been shown to be important in several
human cancers. Studies on expression levels of TP at
different stages of tumor development have suggested that
TP is important in early neovascularization although its role
in colon cancer progression remains to be determined [74].
3.5. Dihydropyrimidine dehydrogenase (DPD) levels
DPD catalyzes the major catabolic step in pyrimidine
metabolism. Lack of DPD expression correlates with 5-FU
toxicity in patients and sometimes can even be fatal. How-
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ever, low levels of DPD in colorectal tumors have been
shown to add to the predictive of low TS and to correlate
with response to 5-FU-based chemotherapy [75]. This corre-
lation holds true for mRNA levels as well as protein levels. As
further evidence for the involvement of DPD in 5-FU
resistance, we have recently demonstrated that overexpres-
sion of human DPD in NIH 3T3 cells leads to increased
resistance to 5-FU. Murine bone marrow stem cells trans-
duced with a retroviral construct containing DPD cDNA and
expressing higher levels of the protein show increased
number of drug resistant colonies as measured by the CFU-
GM assay. Similar increase in 5-FU resistant CFU-GM
colonies were obtained when human peripheral blood stem
cells were transduced with the retroviral construct bearing
DPD cDNA [76].
Of the various enzymatic steps depicted above, reactions
catalyzed by enzymes OPRTase, UMPK, TS, TP, and DPD
appear to have greater impact on fluoropyrimidine response
than DHFR and TK. Levels of OPRTase, UMPK, TS, TP,
and DPD have all now been shown to be correlated with
clinical response to the fluoropyrimidine therapy. Accord-
ingly, determinations of levels of this panel of enzyme prior
to chemotherapy may allow one to predict response.
4. Strategies to overcome or exploit antifolate resistance
The observation that defective transport was a common
mechanism of resistance to MTX in ALL has prompted the
use of lipophilic antifolates such as trimetrexate (TMTX),
which do not use the RFC to enter cells. TMTX has now
been approved for use against Pneumocystis carinii infec-
tions in acquired immunodeficiency syndrome (AIDS)
patients without severe side effects because of the simulta-
neous administration of 5-formyltetrahydrofolate (leuco-
vorin: LV). The combination of TMTX and LV rescues
the host cells from TMTX toxicity but is toxic to the parasite
cells as they have no RFC and hence cannot take up LV.
This selectivity has encouraged use of TMTX to target
transport-deficient MTX-resistant cells with the TMTX–
LV combination. Initial in vitro studies with CCRF–CEM
cells have shown that transport-deficient MTX-resistant
cells are sensitive to TMTX while the MTX-sensitive cells
can be protected by LV. In order to test this concept in an
animal model, SCID mice bearing tumors from transport-
deficient MTX-resistant CCRF–CEM ALL cells were trea-
ted with the TMTX–LV combination, which led to tumor
regression without any significant toxicity [77].
4.1. Myeloprotection using drug resistance genes
Introduction and efficient expression of drug-resistant
genes such as mutant DHFR cDNAs into bone marrow
progenitor cells should allow further dose intensification
and has the potential to increase the cure rate for drug
sensitive tumors. Using retroviral constructs containing a
mutant human DHFR cDNA (the Ser31 mutant), we have
infected mouse marrow progenitor cells and have trans-
planted irradiated mice with these transduced cells. Mice
receiving transduced marrow progenitor cells were pro-
tected from the lethal effects of MTX while the controls
died [78,79]. Human CD34+ peripheral blood stem cells
transduced with the Ser31 DHFR cDNA were less sensitive
to MTX than mock transduced controls [80]. We have
initiated studies using the Ser31/Phe22 double mutant of
DHFR cDNA (dmDHFR) as the double mutant form of
the enzyme has been shown to impart greater resistance to
MTX than the single mutants [81]. Our results indicate that
CD34+ stem cells transduced with the dmDHFR are less
sensitive to MTX than mock transduced cells. We plan to
exploit this system for cotransduction and ultimate in vivo
selection of nonselectable genes [82]. We are currently
evaluating myeloprotection in animal model systems using
both mutant human TS genes (mhTS) as well fusion
mDHFR–mhTS genes. (Capiaux et al., in preparation).
We have recently shown that transplantation of bone mar-
row progenitor cells retrovirally transduced and expressing
two drug-resistance genes in a construct SFG–dmDHFR–
CD and SFG–dmDHFR–IRES–ALDH can protect against
a combination of chemotherapeutic agents using either
MTX and Ara-C or MTX and cyclophosphamide, respec-
tively [83,84]. This suggests that the fusion genes may be
very useful for protection against a combination of drugs
that are often used in cancer chemotherapy.
4.2. Exploiting translational regulation of DHFR for
monitoring in vivo gene expression
The ‘‘induction’’ of wild-type DHFR protein in cancer
cells exposed to antifolates has been reported by this
laboratory [49a,b]. Such translational upregulation after
antifolate treatment may also occur for fusion proteins,
e.g. comprising DHFR and herpes simplex virus type 1
thymidine kinase (HSVTK). Since a high intracellular level
of the DHFRF/S fusion protein may improve the therapeutic
use of the HSVTK/GCV therapy, we generated a retroviral
construct containing this fusion cDNA and investigated the
possibility of induction of the fusion protein by antifolates.
The retroviral vectors generated contain a double mutant
(Phe22–Ser31 referred to as F/S), single mutant Ser31 or
wild-type DHFR gene, fused to the HSV1Tk gene.
HCT-8 cells were transduced and selected in 100 nM
TMTX and then exposed to ganciclovir (GCV). The TMTX
selected cells were over two logs more sensitive to GCV
than the untransduced or transduced but unselected cells,
correlating with the expression of the fusion protein [85].
4.2.1. In vivo imaging of DHFR–HSVTK gene expression
using 124I-FIAU
An animal model using RNU (nude) rats and tumors
generated from untransduced HCT-8 cells and HCT-8 trans-
duced with the DHFR–HSVTK fusion gene was set up in
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the following manner. Animals were injected with 106 cells
in the left flank with HCT-8 untransduced cells and in the
right flank with DHFR–HSVTK transduced HCT-8 cells,
respectively. At 12 days postinjection, palpable tumors were
observed in both flanks. The animals were then treated with
a previously established maximum tolerated dose of TMTX.
A control group of animals was treated with the same
volume of vehicle. The immobilized animals (six at a time)
were positioned on a specially designed animal holder and
placed within the positron emission tomography (PET)
scanner (GE Advanced Scanner). The excitation scan was
of 20-min duration and the transmission scan was of 7-min
duration. At the end of the imaging session, a digital image
of the animal showing the flank tumors was also recorded in
order to superimpose the position of the PET scanning
image with the tumor location. To quantitate radioactivity
retained in the tumor versus background radioactivity in
tissues, the animals were sacrificed and counts in tumors,
plasma and muscle tissue were determined by scintillation
counting. Results of the PET imaging and the scintillation
counting indicate that treatment of tumor-bearing animals
with TMTX resulted in increased expression of the fusion
gene expressing both DHFR and HSVTK (Mayer-Kuckuk
et al., submitted for publication, 2001).
4.2.2. Imaging DHFR gene expression using DHFR–EGFP
In order to circumvent the use of isotopes for imaging,
we have initiated work with other fusion genes such as
DHFR–EGFP to monitor gene expression in vivo using
fluorescence microscopy. We have established in an AM12
(transduced with a SFG–DHFR–EGFP retroviral construct)
cell culture model that the induction of the DHFR–EGFP
fusion protein is comparable to the induction of the native
DHFR protein in response to antifolate treatment. Moreover,
this induction is not prevented by addition of ActD but can
be inhibited by cycloheximide treatment. The induction in
DHFR–EGFP protein levels is specific to the antifolate
treatment of cells and is not observed when other drugs such
as fluoropyrimidines, etoposide or doxorubicin are used.
5. Conclusions and perspectives
Study of resistance to drugs such as MTX and 5-FU
continue to reveal interesting and often novel mechanisms,
both intrinsic and acquired. With available molecular tech-
niques, it is now possible to examine which of the resistance
mechanisms studied in cell culture models are operative in
tumor samples from cancer patients treated with the drugs.
These studies, on tumor biopsies prior to chemotherapy,
may help predict tumor response to the chemotherapy.
Myeloprotection strategies based on use of mutant forms
of DHFR and TS are poised to enter clinical trials and will
test the hypothesis that higher doses of drugs can be used in
a posttransplant situation without the risk of myelosup-
pression.
Translational regulation of DHFR is being exploited for
noninvasive in vivo imaging of tumors. We have developed
fusion proteins of DHFR and HSVTK for PET imaging as
well as DHFR and EGFP for optical imaging. We also plan
to explore the possibility of using fusion genes of DHFR to
increase intracellular levels of gene products that may be of
therapeutic benefit.
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